Impact of unbalanced karyotypes at diagnosis on prognosis of CML.

被引：0
|
作者：
Hehlmann, Ruediger
Kalmanti, Lida
Dietz, Christian
Lauseker, Michael
Haferlach, Claudia
Schlegelberger, Brigitte
Jotterand, Martine
Mueller, Martin C.
Haenel, Mathias
Koehne, Claus-Henning
Goebeler, Maria-Elisabeth
Pfreundschuh, Michael
Balleisen, Leopold
Burchert, Andreas
Krause, Stefan W.
Pfirrmann, Markus
Hasford, Joerg
Hochhaus, Andreas
Saussele, Susanne
Fabarius, Alice
机构：
[1] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[2] Univ Munich, Inst Med Informat Verarbeitung Biometrie & Epidem, Munich, Germany
[3] MLL, Munich, Germany
[4] Hannover Med Sch, Inst Zell & Mol Pathol, D-30623 Hannover, Germany
[5] Serv Genet Med, Lausanne, Switzerland
[6] Klinikum Chemnitz, Innere Med Klin 3, Chemnitz, Germany
[7] Klinikum Oldenburg, Klin Onkol & Hamatol, Oldenburg, Germany
[8] ZIM, Med Klin 2, Wurzburg, Germany
[9] Univ Klinikum Saarlandes, Homburg, Saar, Germany
[10] Evangel Krankenhaus Hamm, Hamatol Onkol Abt, Hamm, Germany
[11] Univ Klinikum Giessen & Marburg GmbH, Standort Marburg, Marburg, Germany
[12] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany
[13] Univ Klinikum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7041
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Chromosome 7 short arm deletions and disease progression in CML.
    Poppe, B
    Van Limbergen, H
    Janssens, A
    Van Roy, N
    De Moerloose, B
    Phillipé, J
    De Paepe, A
    Offner, F
    Speleman, F
    BLOOD, 1999, 94 (10) : 212B - 212B
  • [32] Impaired DC maturation and antileukemic T cell anergy in CML.
    Eisendle, K
    Lang, A
    Eibl, B
    Nachbaur, D
    Gastl, G
    BLOOD, 2002, 100 (11) : 325B - 325B
  • [33] Cellular, morphological and molecular characteristics of a cell line model of CML.
    Mills, KI
    Guinn, BA
    Walsh, V
    Gilkes, AF
    LeeJones, L
    Francis, D
    Evans, S
    Burnett, AK
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 5 - 5
  • [34] Increase of erythrocyte MCV predicts a good response to imatinib in CML.
    Holowiecki, J
    Giebel, S
    Konopka, L
    Bober, G
    Kruzel, T
    Kopera, M
    BLOOD, 2002, 100 (11) : 326B - 326B
  • [35] Pancytopenia, a complication of Gleevec in treatment of accelerated and chronic phase CML.
    Zalzaleh, G
    Jajeh, A
    BLOOD, 2003, 102 (11) : 310B - 310B
  • [36] Type of BCR/ABL junction and clinical characteristics of CML. Evaluation of 111 CML cases in a single institution
    Palumbo, G
    Specchia, G
    Mininni, D
    Pastore, D
    Pannunzio, A
    Quarta, A
    Ricco, A
    Scorca, A
    Liso, V
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 279 - 279
  • [37] Interleukin-1 α genotype and outcome of unrelated donor BMT for CML.
    Mehta, PA
    Eapen, M
    Gandham, S
    Elliott, J
    Combs, M
    Wilke, T
    Aplenc, R
    MacMillan, ML
    Weisdorf, DJ
    Petersdorf, EW
    Klein, J
    Davies, SM
    BLOOD, 2005, 106 (11) : 582A - 582A
  • [38] Universal approach to web-based chemistry using XML and CML.
    Murray-Rust, P
    Rzepa, HS
    Wright, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U279 - U279
  • [39] Cdc2 (cdk1) is aberrantly expressed in CML.
    Orr, SJ
    Lea, NC
    Mufti, GJ
    Thomas, SN
    BLOOD, 2003, 102 (11) : 194B - 194B
  • [40] Peripheral blood progenitor cell (PBPC) mobilization for autologous transplant (AT) in CML.
    Sureda, A
    Santamaria, A
    Martino, R
    Aventín, A
    Martínez, C
    Amill, B
    Peyret, M
    Brunet, S
    Sierra, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S62 - S62
12345